PDCD1 and Miyoshi myopathy: Finally, in a clinical study exploring this issue, an analysis of 32 individuals with MM treated either with nivolumab or pembrolizumab revealed a notable decrease in the presence of peripheral PD-1+ Treg cells (from 23% to 8.6%, p < 0.05) following the initial cycle of immunotherapy.